Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.59M | -16.38M | -12.73M | -11.93M | -9.92M |
| Total Depreciation and Amortization | -- | -- | 0.00 | 23.70K | 24.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.19M | 4.37M | 4.81M | 3.46M | 3.85M |
| Change in Net Operating Assets | 2.96M | -50.40K | 409.20K | -2.15M | 466.80K |
| Cash from Operations | -12.44M | -12.06M | -7.52M | -10.59M | -5.57M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.91M | -80.48M | -98.80K | -28.75M | 9.84M |
| Cash from Investing | -5.91M | -80.48M | -98.80K | -28.75M | 9.84M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 2.90M | 108.18M | 250.90K | 31.80K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.50K | -- | 385.10K | -385.10K | -- |
| Cash from Financing | -14.50K | 2.90M | 108.57M | -134.10K | 31.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.37M | -89.65M | 100.95M | -39.47M | 4.30M |